Advertisement

Cellular and Molecular Life Sciences

, Volume 71, Issue 14, pp 2681–2698 | Cite as

Physical activity and the endocannabinoid system: an overview

  • Mirko Tantimonaco
  • Roberta Ceci
  • Stefania Sabatini
  • Maria Valeria Catani
  • Antonello Rossi
  • Valeria Gasperi
  • Mauro Maccarrone
Review

Abstract

Recognized as a “disease modifier”, physical activity (PA) is increasingly viewed as a more holistic, cost-saving method for prevention, treatment and management of human disease conditions. The traditional view that PA engages the monoaminergic and endorphinergic systems has been challenged by the discovery of the endocannabinoid system (ECS), composed of endogenous lipids, their target receptors, and metabolic enzymes. Indeed, direct and indirect evidence suggests that the ECS might mediate some of the PA-triggered effects throughout the body. Moreover, it is now emerging that PA itself is able to modulate ECS in different ways. Against this background, in the present review we shall discuss evidence of the cross-talk between PA and the ECS, ranging from brain to peripheral districts and highlighting how ECS must be tightly regulated during PA, in order to maintain its beneficial effects on cognition, mood, and nociception, while avoiding impaired energy metabolism, oxidative stress, and inflammatory processes.

Keywords

Adaptive responses Endocannabinoids Exercise Health benefit Physical activity 

Notes

Acknowledgments

We apologize in advance to all investigators whose research could not be appropriately quoted due to space limitations. We wish to thank all colleagues who have contributed over the past 15 years to our studies of the endocannabinoid system and its impact on human health and disease. Financial support from Fondazione TERCAS (Grant n° 2009–2012), Ministero dell’Istruzione, dell’Università e della Ricerca (grant n° PRIN 2010–2011), Fondazione Italiana Sclerosi Multipla (FISM grant 2010), to M.M., and from Regione Lazio (grant n° 00011377/2010–2013) to M.T. is also gratefully acknowledged.

References

  1. 1.
    Howley ET (2001) Type of activity: resistance, aerobic and leisure versus occupational PA. Med Sci Sports Exerc 33:S364–S369 (discussion S419–420)PubMedGoogle Scholar
  2. 2.
    Romijn JA et al (1993) Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol 265:E380–E391PubMedGoogle Scholar
  3. 3.
    Yau SY et al (2012) Effects of voluntary running on plasma levels of neurotrophins, hippocampal cell proliferation and learning and memory in stressed rats. Neuroscience 222:289–301PubMedGoogle Scholar
  4. 4.
    Knab AM, Lightfoot JT (2010) Does the difference between physically active and couch potato lie in the dopamine system? Int J Biol Sci 6:133–150PubMedCentralPubMedGoogle Scholar
  5. 5.
    Nijs J et al (2012) Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? Pain Physician 151:ES205–213Google Scholar
  6. 6.
    Gleeson M, Walsh NP (2012) British Association of Sport and Exercise Sciences. The BASES expert statement on exercise, immunity, and infection. J Sports Sci 30:321–324PubMedGoogle Scholar
  7. 7.
    Pedersen L, Hojman P (2012) Muscle-to-organ cross talk mediated by myokines. Adipocyte 1:164–167PubMedCentralPubMedGoogle Scholar
  8. 8.
    Voss MW et al (2011) Exercise, brain, and cognition across the life span. J Appl Physiol 111:1505–1513PubMedCentralPubMedGoogle Scholar
  9. 9.
    Mora S et al (2007) Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 116:2110–2118PubMedCentralPubMedGoogle Scholar
  10. 10.
    Alexanderson H, Lundberg IE (2012) Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 24:201–207PubMedGoogle Scholar
  11. 11.
    Church T (2011) Exercise in obesity, metabolic syndrome, and diabetes. Prog Cardiovasc Dis 53:412–418PubMedGoogle Scholar
  12. 12.
    Proske U, Morgan DL (2001) Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications. J Physiol 537:333–345PubMedCentralPubMedGoogle Scholar
  13. 13.
    Zaldivar F et al (2006) Constitutive pro- and anti-inflammatory cytokine and growth factor response to exercise in leukocytes. J Appl Physiol 100:1124–1133PubMedGoogle Scholar
  14. 14.
    Carek PJ et al (2011) Exercise for the treatment of depression and anxiety. Int J Psychiatry Med 41:15–28PubMedGoogle Scholar
  15. 15.
    Waters RP et al (2013) Selection for increased voluntary wheel-running affects behavior and brain monoamines in mice. Brain Res 1508:9–22PubMedCentralPubMedGoogle Scholar
  16. 16.
    Milman S et al (2012) Opioid receptor blockade prevents exercise-associated autonomic failure in humans. Diabetes 61:1609–1615PubMedCentralPubMedGoogle Scholar
  17. 17.
    Howlett AC et al (2010) CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem 17:1382–1393PubMedCentralPubMedGoogle Scholar
  18. 18.
    Pertwee RG et al (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588–631PubMedCentralPubMedGoogle Scholar
  19. 19.
    Devane WA et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedGoogle Scholar
  20. 20.
    Sugiura T et al (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89–97PubMedGoogle Scholar
  21. 21.
    Mechoulam R et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90PubMedGoogle Scholar
  22. 22.
    De Petrocellis L, Di Marzo V (2009) An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 23:1–15PubMedGoogle Scholar
  23. 23.
    Hanus et al (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662–3665PubMedCentralPubMedGoogle Scholar
  24. 24.
    Porter AC et al (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020–1024PubMedGoogle Scholar
  25. 25.
    Huang SM et al (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400–8405PubMedCentralPubMedGoogle Scholar
  26. 26.
    Brown I et al (2010) Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31:1584–1591PubMedCentralPubMedGoogle Scholar
  27. 27.
    Rovito D et al (2013) Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARγ activation in MCF-7 breast cancer cells. J Cell Physiol 228:1314–1322PubMedGoogle Scholar
  28. 28.
    Klein TW et al (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486–496PubMedGoogle Scholar
  29. 29.
    Patel KD et al (2010) Cannabinoid CB(2) receptors in health and disease. Curr Med Chem 17:1393–1410PubMedGoogle Scholar
  30. 30.
    Viscomi MT et al (2009) Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 29:4564–4570PubMedGoogle Scholar
  31. 31.
    Ross RA (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30:156–163PubMedGoogle Scholar
  32. 32.
    Gasperi V et al (2013) GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Curr Med Chem 20:64–78PubMedGoogle Scholar
  33. 33.
    Di Marzo V, De Petrocellis L (2010) Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 17:1430–1449PubMedGoogle Scholar
  34. 34.
    Greco R et al (2010) The endocannabinoid system and migraine. Exp Neurol 224:85–91PubMedGoogle Scholar
  35. 35.
    Maccarrone M et al (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275:31938–31945PubMedGoogle Scholar
  36. 36.
    Stock K et al (2012) Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med 18:1232–1238PubMedGoogle Scholar
  37. 37.
    Bouaboula M et al (2005) Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517:174–181PubMedGoogle Scholar
  38. 38.
    Gasperi V et al (2007) Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64:219–229PubMedGoogle Scholar
  39. 39.
    Rockwell CE et al (2006) Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70:101–111PubMedGoogle Scholar
  40. 40.
    Okamoto Y et al (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298–5305PubMedGoogle Scholar
  41. 41.
    Ueda N et al (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 280:1874–1894PubMedGoogle Scholar
  42. 42.
    Gasperi V et al (2014) The fatty acid amide hydrolase in lymphocytes from sedentary and active subjects. Med Sci Sports Exerc 46:24–32PubMedGoogle Scholar
  43. 43.
    Giuffrida A et al (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363PubMedGoogle Scholar
  44. 44.
    Malcher-Lopes R et al (2006) Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 26:6643–6650PubMedGoogle Scholar
  45. 45.
    Silvestri C, Di Marzo V (2013) The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 17:475–490PubMedGoogle Scholar
  46. 46.
    Maccarrone M et al (2001) Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 393:321–328PubMedGoogle Scholar
  47. 47.
    Liu J et al (2003) Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 278:45034–45039PubMedGoogle Scholar
  48. 48.
    Maccarrone M et al (2010) Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35:601–608PubMedGoogle Scholar
  49. 49.
    Liu J et al (2006) A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103:13345–13350PubMedCentralPubMedGoogle Scholar
  50. 50.
    Simon GM, Cravatt BF (2010) Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol BioSyst 6(8):1411–1418PubMedCentralPubMedGoogle Scholar
  51. 51.
    Chicca A et al (2012) Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem 287:34660–34682PubMedCentralPubMedGoogle Scholar
  52. 52.
    Fowler CJ (2012) Anandamide uptake explained? Trends Pharmacol Sci 33:181–185PubMedGoogle Scholar
  53. 53.
    Oddi S et al (2008) Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci 65:840–850PubMedGoogle Scholar
  54. 54.
    McKinney MK, Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411–432PubMedGoogle Scholar
  55. 55.
    Fezza F et al (2008) Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 49:101–132PubMedGoogle Scholar
  56. 56.
    Wei BQ et al (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281:36569–36578PubMedGoogle Scholar
  57. 57.
    Bisogno T et al (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463–468PubMedCentralPubMedGoogle Scholar
  58. 58.
    Dinh TP et al (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819–10824PubMedCentralPubMedGoogle Scholar
  59. 59.
    Blankman JL et al (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347–1356PubMedCentralPubMedGoogle Scholar
  60. 60.
    Marrs WR et al (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13:951–957PubMedCentralPubMedGoogle Scholar
  61. 61.
    Valdeolivas S et al (2013) The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis 4:e862PubMedCentralPubMedGoogle Scholar
  62. 62.
    Nomura DK (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334(6057):809–813PubMedCentralPubMedGoogle Scholar
  63. 63.
    Sparling PB, Dietrich A et al (2003) Exercise activates the endocannabinoid system. Neuroreport 14:2209–2211PubMedGoogle Scholar
  64. 64.
    Feuerecker M et al (2012) Effects of exercise stress on the endocannabinoid system in humans under field conditions. Eur J Appl Physiol 112:2777–2781PubMedGoogle Scholar
  65. 65.
    Heyman E et al (2012) Intense exercise increases circulating endocannabinoid and BDNF levels in humans—possible implications for reward and depression. Psychoneuroendocrinology 37:844–851PubMedGoogle Scholar
  66. 66.
    Raichlen DA et al (2012) Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the ‘runner’s high’. J Exp Biol 215:1331–1336PubMedGoogle Scholar
  67. 67.
    Raichlen DA et al (2012) Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol 113:869–875PubMedGoogle Scholar
  68. 68.
    Di Marzo V et al (2009) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52:213–217PubMedGoogle Scholar
  69. 69.
    You T et al (2011) Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis 10:194PubMedCentralPubMedGoogle Scholar
  70. 70.
    Hill MN et al (2010) Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus 20:513–523PubMedCentralPubMedGoogle Scholar
  71. 71.
    Galdino G et al (2013) The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology 77C:313–324Google Scholar
  72. 72.
    De Chiara V et al (2010) Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 35:374–387PubMedCentralPubMedGoogle Scholar
  73. 73.
    Gomes da Silva S et al (2010) Physical exercise in adolescence changes CB1 cannabinoid receptor expression in the rat brain. Neurochem Int 57:492–496PubMedGoogle Scholar
  74. 74.
    Yan ZC et al (2007) Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354:427–433PubMedGoogle Scholar
  75. 75.
    Middleton FA, Strick PL (2000) Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Brain Res Rev 31:236–250PubMedGoogle Scholar
  76. 76.
    Ade KK, Lovinger DM (2007) Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum. J Neurosci 27:2403–2439PubMedGoogle Scholar
  77. 77.
    Su LD et al (2013) Retrograde cPLA(2)α/arachidonic acid/2-AG signaling is essential for cerebellar depolarization-induced suppression of excitation and long-term potentiation. Cerebellum 12:297–299PubMedGoogle Scholar
  78. 78.
    Kyriakatos A, El Manira A (2007) Long-term plasticity of the spinal locomotor circuitry mediated by endocannabinoid and nitric oxide signaling. J Neurosci 27:12664–12674PubMedGoogle Scholar
  79. 79.
    Song J et al (2012) Gating the polarity of endocannabinoid-mediated synaptic plasticity by nitric oxide in the spinal locomotor network. J Neurosci 32:5097–5105PubMedGoogle Scholar
  80. 80.
    Díaz-Alonso J et al (2012) The CB(1) cannabinoid receptor drives corticospinal motor neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis. J Neurosci 32:16651–16665PubMedCentralPubMedGoogle Scholar
  81. 81.
    Newman Z et al (2007) Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci 25:1619–1630PubMedCentralPubMedGoogle Scholar
  82. 82.
    Huerta M et al (2009) Effects of cannabinoids on caffeine contractures in slow and fast skeletal muscle fibers of the frog. J Membr Biol 229:91–99PubMedCentralPubMedGoogle Scholar
  83. 83.
    James RS et al (2011) Variation in expression of calcium-handling proteins is associated with inter-individual differences in mechanical performance of rat (Rattus norvegicus) skeletal muscle. J Exp Biol 214:3542–3548PubMedGoogle Scholar
  84. 84.
    Seebacher F et al (2012) How well do muscle biomechanics predict whole-animal locomotor performance? The role of Ca2+ handling. J Exp Biol 215:1847–1853PubMedGoogle Scholar
  85. 85.
    Mahmmoud YA, Gaster M (2012) Uncoupling of sarcoplasmic reticulum Ca2+-ATPase by N-arachidonoyl dopamine. Members of the endocannabinoid family as thermogenic drugs. Br J Pharmacol 166:2060–2069PubMedCentralPubMedGoogle Scholar
  86. 86.
    Oz M et al (2000) Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca(2+) fluxes in rabbit T-tubule membranes. Eur J Pharmacol 404:13–20PubMedGoogle Scholar
  87. 87.
    Alptekin A et al (2010) The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. Eur J Pharmacol 634:10–15PubMedGoogle Scholar
  88. 88.
    Wiley JL (2003) Sex-dependent effects of delta 9-tetrahydrocannabinol on locomotor activity in mice. Neurosci Lett 352:77–80PubMedGoogle Scholar
  89. 89.
    Pandolfo P et al (2007) Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2. Eur J Pharmacol 563:141–148PubMedGoogle Scholar
  90. 90.
    Smirnov MS, Kiyatkin EA (2008) Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats. Brain Res 1228:145–160PubMedCentralPubMedGoogle Scholar
  91. 91.
    Dubreucq S et al (2010) CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol 224:106–113PubMedGoogle Scholar
  92. 92.
    Tallett AJ et al (2007) Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 195:27–39PubMedGoogle Scholar
  93. 93.
    Keeney BK et al (2008) Differential response to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour. Behav Pharmacol 19:812–820PubMedGoogle Scholar
  94. 94.
    Keeney BK et al (2012) Sex differences in cannabinoid receptor-1 (CB1) pharmacology in mice selectively bred for high voluntary wheel-running behavior. Pharmacol Biochem Behav 101:528–537PubMedGoogle Scholar
  95. 95.
    Maccarrone M et al (2006) Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 95:117–127PubMedGoogle Scholar
  96. 96.
    Stranahan AM et al (2008) Central mechanisms of HPA axis regulation by voluntary exercise. Neuromolecular Med 10:118–127PubMedCentralPubMedGoogle Scholar
  97. 97.
    Duric V, Duman RS (2013) Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 70:39–53PubMedCentralPubMedGoogle Scholar
  98. 98.
    Compagnucci C et al (2013) Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells. PLoS One 8(1):e54271PubMedCentralPubMedGoogle Scholar
  99. 99.
    Jiang W et al (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115:3104–3116PubMedCentralPubMedGoogle Scholar
  100. 100.
    Jin K et al (2004) Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 66:204–208PubMedGoogle Scholar
  101. 101.
    Aguado T et al (2006) The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 26:1551–1561PubMedGoogle Scholar
  102. 102.
    Aso E et al (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105:565–572PubMedGoogle Scholar
  103. 103.
    Butovsky E et al (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 93:802–811PubMedGoogle Scholar
  104. 104.
    Varvel SA et al (2007) Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 32:1032–1041PubMedGoogle Scholar
  105. 105.
    Mazzola C et al (2009) Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16:332–337PubMedCentralPubMedGoogle Scholar
  106. 106.
    Goonawardena AV et al (2011) Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus. Neuropharmacology 61:1016–1025PubMedCentralPubMedGoogle Scholar
  107. 107.
    Chiew KS, Braver TS (2011) Positive affect versus reward: emotional and motivational influences on cognitive control. Front Psychol 2:279PubMedCentralPubMedGoogle Scholar
  108. 108.
    Ganon-Elazar E, Akirav I (2012) Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress. Neuropsychopharmacology 37(2):456–466PubMedCentralPubMedGoogle Scholar
  109. 109.
    Campeau S et al (2010) Hypothalamic pituitary adrenal axis responses to low-intensity stressors are reduced after voluntary wheel running in rats. J Neuroendocrinol 22:872–888PubMedGoogle Scholar
  110. 110.
    Bisicchia E et al (2013) Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor α: when one is better than two. Cell Mol Life Sci 70:2191–2204PubMedGoogle Scholar
  111. 111.
    Elbatsh MM et al (2012) Antidepressant-like effects of Δ9-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression. Pharmacol Biochem Behav 102:357–365PubMedGoogle Scholar
  112. 112.
    Bortolato M et al (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103–1110PubMedGoogle Scholar
  113. 113.
    Le Foll B et al (2009) The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology 205:171–174PubMedCentralPubMedGoogle Scholar
  114. 114.
    Martin M et al (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159:379–387PubMedGoogle Scholar
  115. 115.
    Steiner MA et al (2008) Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33:54–67PubMedCentralPubMedGoogle Scholar
  116. 116.
    Dubreucq S et al (2012) Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance. Biol Psychiatry 73:895–903PubMedGoogle Scholar
  117. 117.
    Solinas M et al (2008) The endocannabinoid system in brain reward processes. Br J Pharmacol 154:369–383PubMedCentralPubMedGoogle Scholar
  118. 118.
    Smith MA et al (2008) Aerobic exercise decreases the positive-reinforcing effects of cocaine. Drug Alcohol Depend 98:129–135PubMedCentralPubMedGoogle Scholar
  119. 119.
    Buchowski MS et al (2011) Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. PLoS One 6:e17465PubMedCentralPubMedGoogle Scholar
  120. 120.
    Smith SL, Rasmussen EB (2010) Effects of 2-AG on the reinforcing properties of wheel activity in obese and lean Zucker rats. Behav Pharmacol 21:292–300PubMedGoogle Scholar
  121. 121.
    Drew LJ et al (2002) Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12:2079–2086Google Scholar
  122. 122.
    Tsou K et al (1996) Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 70:791–798PubMedGoogle Scholar
  123. 123.
    Lichtman AH et al (2004) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109:319–327PubMedGoogle Scholar
  124. 124.
    Caprioli A et al (2012) The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J Pharmacol Exp Ther 342:188–195PubMedGoogle Scholar
  125. 125.
    Ghafouri N et al (2013) Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain 154:1649–1658PubMedGoogle Scholar
  126. 126.
    Blundell JE et al (2012) Role of resting metabolic rate and energy expenditure in hunger and appetite control: a new formulation. Dis Model Mech 5:608–613PubMedCentralPubMedGoogle Scholar
  127. 127.
    Rämson R et al (2012) The effect of 4-week training period on plasma neuropeptide Y, leptin and ghrelin responses in male rowers. Eur J Appl Physiol 112:1873–1880PubMedGoogle Scholar
  128. 128.
    de Rijke CE et al (2005) Hypothalamic neuropeptide expression following chronic food restriction in sedentary and wheel-running rats. J Mol Endocrinol 35:381–390PubMedGoogle Scholar
  129. 129.
    Ghanbari-Niaki A et al (2007) Plasma agouti-related protein (AGRP), growth hormone, insulin responses to a single circuit-resistance exercise in male college students. Peptides 28:1035–1039PubMedGoogle Scholar
  130. 130.
    Pil-Byung C et al (2011) Effects of exercise program on appetite-regulating hormones, inflammatory mediators, lipid profiles, and body composition in healthy men. J Sports Med Phys Fitness 51:654–663PubMedGoogle Scholar
  131. 131.
    Shadid S et al (2006) Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 91:3418–3425PubMedGoogle Scholar
  132. 132.
    Bouassida A et al (2010) Review on leptin and adiponectin responses and adaptations to acute and chronic exercise. Br J Sports Med 44:620–630PubMedGoogle Scholar
  133. 133.
    Martins C et al (2007) Effects of exercise on gut peptides, energy intake and appetite. J Endocrinol 193:251–258PubMedGoogle Scholar
  134. 134.
    Broom DR et al (2009) Influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide YY in healthy males. Am J Physiol Regul Integr Comp Physiol 296:R29–R35PubMedGoogle Scholar
  135. 135.
    Maccarrone M et al (2010) The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 30:423–440PubMedGoogle Scholar
  136. 136.
    Kirkham TC et al (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550–557PubMedCentralPubMedGoogle Scholar
  137. 137.
    Di Marzo V et al (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822–825PubMedGoogle Scholar
  138. 138.
    Kola B et al (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196–25201PubMedGoogle Scholar
  139. 139.
    Gamber KM et al (2005) Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 49:646–652PubMedGoogle Scholar
  140. 140.
    Osei-Hyiaman D et al (2005) Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81:273–282PubMedGoogle Scholar
  141. 141.
    Wiley JL et al (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293–300PubMedCentralPubMedGoogle Scholar
  142. 142.
    Soria-Gómez E et al (2007) Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151:1109–1116PubMedCentralPubMedGoogle Scholar
  143. 143.
    Cristino L et al (2013) Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proc Natl Acad Sci USA 110:E2229–E2238PubMedCentralPubMedGoogle Scholar
  144. 144.
    Zhou D, Shearman LP (2004) Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice. Pharmacol Biochem Behav 77:117–125PubMedGoogle Scholar
  145. 145.
    Chinsomboon J et al (2009) The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci USA 106:21401–21406PubMedCentralPubMedGoogle Scholar
  146. 146.
    Goodpaster BH et al (2003) Enhanced fat oxidation through PA is associated with improvements in insulin sensitivity in obesity. Diabetes 52:2191–2197PubMedGoogle Scholar
  147. 147.
    Lavoie JM, Gauthier MS (2006) Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 63:1393–1409PubMedGoogle Scholar
  148. 148.
    Perseghin G et al (2007) Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 30:683–688PubMedGoogle Scholar
  149. 149.
    Jeppesen J, Kiens B (2012) Regulation and limitations to fatty acid oxidation during exercise. J Physiol 590:1059–1068PubMedCentralPubMedGoogle Scholar
  150. 150.
    Di Marzo V et al (2009) Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 161:715–722PubMedGoogle Scholar
  151. 151.
    Lindborg KA et al (2010) Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obes Metab 12:722–730PubMedGoogle Scholar
  152. 152.
    Esposito I et al (2008) The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 74:1678–1686PubMedGoogle Scholar
  153. 153.
    Lipina C et al (2010) Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 59:375–385PubMedCentralPubMedGoogle Scholar
  154. 154.
    Agudo J et al (2010) Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 53:2629–2640PubMedGoogle Scholar
  155. 155.
    Aguirre V et al (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531–1537PubMedGoogle Scholar
  156. 156.
    Eckardt K et al (2009) Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 52(4):664–674PubMedGoogle Scholar
  157. 157.
    Fazakerley DJ et al (2010) Kinetic evidence for unique regulation of GLUT4 trafficking by insulin and AMP-activated protein kinase activators in L6 myotubes. J Biol Chem 285(3):1653–1660PubMedCentralPubMedGoogle Scholar
  158. 158.
    Yang J, Holman GD (2006) Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis. Endocrinology 147(6):2728–2736PubMedGoogle Scholar
  159. 159.
    Moreno-Navarrete JM et al (2012) The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 61:281–291PubMedCentralPubMedGoogle Scholar
  160. 160.
    Perwitz N et al (2006) Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 38:356–368PubMedGoogle Scholar
  161. 161.
    Gary-Bobo M et al (2006) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471–478PubMedGoogle Scholar
  162. 162.
    Jbilo O et al (2005) The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567–1569PubMedGoogle Scholar
  163. 163.
    Nogueiras R et al (2008) Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977–2991PubMedCentralPubMedGoogle Scholar
  164. 164.
    Fredenrich A, Grimaldi PA (2005) PPAR delta: an uncompletely known nuclear receptor. Diabetes Metab 31:23–27PubMedGoogle Scholar
  165. 165.
    Maccarrone M et al (2004) Differential regulation of fatty acid amide hydrolase promoter in human immune cells and neuronal cells by leptin and progesterone. Eur J Biochem 271:4666–4676PubMedGoogle Scholar
  166. 166.
    Cravatt BF et al (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371–9376PubMedCentralPubMedGoogle Scholar
  167. 167.
    Osei-Hyiaman D et al (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160–3169PubMedCentralPubMedGoogle Scholar
  168. 168.
    Jourdan T et al (2010) CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 59:926–934PubMedCentralPubMedGoogle Scholar
  169. 169.
    Yasari S et al (2012) Effects of exercise training on molecular markers of lipogenesis and lipid partitioning in fructose-induced liver fat accumulation. J Nutr Metab 2012:181687PubMedCentralPubMedGoogle Scholar
  170. 170.
    Simpson RJ (2011) Aging, persistent viral infections, and immunosenescence: can exercise “make space”? Exerc Sport Sci Rev 39:23–33PubMedGoogle Scholar
  171. 171.
    Gannon GA et al (2001) Differential cell adhesion molecule expression and lymphocyte mobilisation during prolonged aerobic exercise. Eur J Appl Physiol 84:272–282PubMedGoogle Scholar
  172. 172.
    Pedersen BK et al (1988) Modulation of natural killer cell activity in peripheral blood by physical exercise. Scand J Immunol 27:673–678PubMedGoogle Scholar
  173. 173.
    Scott JP et al (2011) Effect of exercise intensity on the cytokine response to an acute bout of running. Med Sci Sports Exerc 43:2297–2306PubMedGoogle Scholar
  174. 174.
    Timmerman KL et al (2008) Exercise training-induced lowering of inflammatory (CD14+ CD16+) monocytes: a role in the anti-inflammatory influence of exercise? J Leukoc Biol 84:1271–1278PubMedGoogle Scholar
  175. 175.
    Wang J et al (2011) Effect of exercise training intensity on murine T-regulatory cells and vaccination response. Scand J Med Sci Sports 22:643–652PubMedGoogle Scholar
  176. 176.
    Kawanishi N et al (2010) Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc Immunol Rev 16:105–118PubMedGoogle Scholar
  177. 177.
    Pedersen BK (2009) The diseasome of physical inactivity—and the role of myokines in muscle—fat cross talk. J Physiol 587:5559–5568PubMedCentralPubMedGoogle Scholar
  178. 178.
    Pournot H et al (2011) Time-course of changes in inflammatory response after whole-body cryotherapy multi exposures following severe exercise. PLoS One 6:e22748PubMedCentralPubMedGoogle Scholar
  179. 179.
    Pedersen BK (2012) Muscular interleukin-6 and its role as an energy sensor. Med Sci Sports Exerc 44:392–396PubMedGoogle Scholar
  180. 180.
    Brooks SV et al (2008) Repeated bouts of aerobic exercise lead to reductions in skeletal muscle free radical generation and nuclear factor kappaB activation. J Physiol 586:3979–3990PubMedCentralPubMedGoogle Scholar
  181. 181.
    Cobley JN et al (2011) N-Acetylcysteine’s attenuation of fatigue after repeated bouts of intermittent exercise: practical implications for tournament situations. Int J Sport Nutr Exerc Metab 21:451–461PubMedGoogle Scholar
  182. 182.
    Sun MW et al (2008) Effects of different levels of exercise volume on endothelium-dependent vasodilation: roles of nitric oxide synthase and heme oxygenase. Hypertens Res 31:805–816PubMedGoogle Scholar
  183. 183.
    Radak Z et al (2012) Nitric oxide: is it the cause of muscle soreness? Nitric Oxide 26:89–94PubMedGoogle Scholar
  184. 184.
    Powers SK et al (2011) Reactive oxygen species: impact on skeletal muscle. Compr Physiol 1:941–969PubMedCentralPubMedGoogle Scholar
  185. 185.
    Villalta SA et al (2009) Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 18:482–496PubMedCentralPubMedGoogle Scholar
  186. 186.
    Chiurchiù V, Maccarrone M (2011) Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 15:2605–2641PubMedGoogle Scholar
  187. 187.
    Coopman K et al (2007) Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol 7:360–371PubMedGoogle Scholar
  188. 188.
    Smith SR et al (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293:136–150PubMedGoogle Scholar
  189. 189.
    Cencioni MT et al (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5:e8688PubMedCentralPubMedGoogle Scholar
  190. 190.
    Pandey R et al (2009) Endocannabinoids and immune regulation. Pharmacol Res 60:85–92PubMedCentralPubMedGoogle Scholar
  191. 191.
    Maccarrone M et al (2000) Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 275:13484–13492PubMedGoogle Scholar
  192. 192.
    Tedesco L et al (2010) Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 59:2826–2836PubMedCentralPubMedGoogle Scholar
  193. 193.
    Mukhopadhyay P et al (2011) Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 50:179–195PubMedCentralPubMedGoogle Scholar
  194. 194.
    Romero TR et al (2012) Involvement of the l-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. J Neurosci Res 90:1474–1479PubMedGoogle Scholar
  195. 195.
    Lee CY et al (2008) A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 8:732–740PubMedGoogle Scholar
  196. 196.
    Kim J et al (2013) Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat 104–105:32–41PubMedGoogle Scholar
  197. 197.
    Ailhaud G et al (2006) Temporal changes in dietary fats: role of n-6 polyunsaturated fatty acids in excessive adipose tissue development and relationship to obesity. Prog Lipid Res 45:203–236PubMedGoogle Scholar

Copyright information

© Springer Basel 2014

Authors and Affiliations

  • Mirko Tantimonaco
    • 1
  • Roberta Ceci
    • 1
  • Stefania Sabatini
    • 1
  • Maria Valeria Catani
    • 2
  • Antonello Rossi
    • 2
  • Valeria Gasperi
    • 2
  • Mauro Maccarrone
    • 3
    • 4
  1. 1.Department of Movement, Human and Health SciencesForo Italico University of RomeRomeItaly
  2. 2.Department of Experimental Medicine and SurgeryTor Vergata University of RomeRomeItaly
  3. 3.Center of Integrated ResearchCampus Bio-Medico University of RomeRomeItaly
  4. 4.European Center for Brain Research/Santa Lucia FoundationRomeItaly

Personalised recommendations